Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1989 1
1993 1
1994 1
1999 1
2002 2
2005 1
2006 1
2007 1
2008 1
2009 3
2010 1
2011 5
2012 4
2013 5
2014 3
2015 2
2016 2
2017 2
2018 7
2019 7
2020 6
Text availability
Article attribute
Article type
Publication date

Search Results

51 results
Results by year
Filters applied: . Clear all
Page 1
Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.
Toljan K, Vrooman B. Toljan K, et al. Med Sci (Basel). 2018 Sep 21;6(4):82. doi: 10.3390/medsci6040082. Med Sci (Basel). 2018. PMID: 30248938 Free PMC article. Review.
Clinical reports of LDN have demonstrated possible benefits in diseases such as fibromyalgia, Crohn's disease, multiple sclerosis, complex-regional pain syndrome, Hailey-Hailey disease, and cancer. ...In general, all of the low-dose features regarding …
Clinical reports of LDN have demonstrated possible benefits in diseases such as fibromyalgia, Crohn's disease, multiple sclerosis, co …
Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.
Li Z, You Y, Griffin N, Feng J, Shan F. Li Z, et al. Int Immunopharmacol. 2018 Aug;61:178-184. doi: 10.1016/j.intimp.2018.05.020. Epub 2018 Jun 7. Int Immunopharmacol. 2018. PMID: 29885638 Review.
Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to eliminate addiction in order to maintain a normal life and prevent or reduce relapse. ...These new discoveries indicate that LDN may become
Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to
Low Dose Naltrexone in Dermatology.
Jaros J, Lio P. Jaros J, et al. J Drugs Dermatol. 2019 Mar 1;18(3):235-238. J Drugs Dermatol. 2019. PMID: 30909326
Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide range of conditions including Crohn’s disease, fibromyalgia, major depressive disorder, cancer, chronic regional pain syndrome, Charc
Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide
Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes.
Trofimovitch D, Baumrucker SJ. Trofimovitch D, et al. Am J Hosp Palliat Care. 2019 Oct;36(10):907-912. doi: 10.1177/1049909119838974. Epub 2019 Mar 27. Am J Hosp Palliat Care. 2019. PMID: 30917675 Review.
Low dose naltrexone has gained popularity as an off-label treatment of several autoimmune diseases including multiple sclerosis and inflammatory bowel disease, as well as chronic pain disorders including fibromyalgia, complex regional pain syndrome, and diabe
Low dose naltrexone has gained popularity as an off-label treatment of several autoimmune diseases including multiple s
Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion.
Miskoff JA, Chaudhri M. Miskoff JA, et al. Cureus. 2018 Jul 5;10(7):e2924. doi: 10.7759/cureus.2924. Cureus. 2018. PMID: 30197847 Free PMC article.
Low dose naltrexone (LDN) has been promising as a complementary medication for patients with a broad range of medical disorders. ...Additionally, clinical trials have proposed a unique mechanism(s) allowing LDN to affect tumors including non-small cell
Low dose naltrexone (LDN) has been promising as a complementary medication for patients with a broad range of medical d
Low-dose naltrexone for disease prevention and quality of life.
Brown N, Panksepp J. Brown N, et al. Med Hypotheses. 2009 Mar;72(3):333-7. doi: 10.1016/j.mehy.2008.06.048. Epub 2008 Nov 28. Med Hypotheses. 2009. PMID: 19041189
The use of low-dose naltrexone (LDN) for the treatment and prophylaxis of various bodily disorders is discussed. Accumulating evidence suggests that LDN can promote health supporting immune-modulation which may reduce various oncogenic and inflammatory autoim …
The use of low-dose naltrexone (LDN) for the treatment and prophylaxis of various bodily disorders is discussed. Accumu …
The Use of Naltrexone in Low Doses Beyond the Approved Indication.
Ringerike T, Pike E, Nevjar J, Klemp M. Ringerike T, et al. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2015 Apr. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 8-2015. Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH). 2015. PMID: 28510411 Free Books & Documents. Review.
Naltrexone in much lower doses than 50 mg has been used in Norway for the treatment of a variety of diseases, such as multiple sclerosis (MS), Crohn's disease, fibromyalgia, cancer, inflammatory bowel disease, chronic fatigue syndrome, and amyotrophic lateral
Naltrexone in much lower doses than 50 mg has been used in Norway for the treatment of a variety of diseases, such as multiple sclero
Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases.
Berkson BM, Rubin DM, Berkson AJ. Berkson BM, et al. Integr Cancer Ther. 2009 Dec;8(4):416-22. doi: 10.1177/1534735409352082. Integr Cancer Ther. 2009. PMID: 20042414 Free article.
The authors, in a previous article, described the long-term survival of a man with pancreatic cancer and metastases to the liver, treated with intravenous alpha-lipoic acid and oral low-dose naltrexone (ALA/N) without any adverse effects. ...In additio …
The authors, in a previous article, described the long-term survival of a man with pancreatic cancer and metastases to the liver, tre …
The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol.
Berkson BM, Rubin DM, Berkson AJ. Berkson BM, et al. Integr Cancer Ther. 2006 Mar;5(1):83-9. doi: 10.1177/1534735405285901. Integr Cancer Ther. 2006. PMID: 16484716 Free article.
The authors describe the long-term survival of a patient with pancreatic cancer without any toxic adverse effects. The treatment regimen includes the intravenous alpha-lipoic acid and low-dose naltrexone (ALA-N) protocol and a healthy lifestyle program …
The authors describe the long-term survival of a patient with pancreatic cancer without any toxic adverse effects. The treatment regi …
The effect of low-dose naltrexone on solid Ehrlich carcinoma in mice: The role of OGFr, BCL2, and immune response.
Aboalsoud A, El-Ghaiesh SH, Abd Elmonem FF, Salem ML, Abdel Rahman MN. Aboalsoud A, et al. Int Immunopharmacol. 2020 Jan;78:106068. doi: 10.1016/j.intimp.2019.106068. Epub 2019 Dec 10. Int Immunopharmacol. 2020. PMID: 31835085
AIMS: Cancer is a major worldwide health problem. Cancer cells express opioid growth factor (OGF) which controls their growth. Naltrexone in low dose (LDN) blocks opioid receptors intermittently and controls the replication of cancer cell …
AIMS: Cancer is a major worldwide health problem. Cancer cells express opioid growth factor (OGF) which controls their growth. …
51 results
Jump to page
Feedback